KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.

Chun-Yan Lan, Jing Zhao, Fan Yang, Ying Xiong, Rong Li, Yu Huang, Jing Wang, Chang Liu, Xue-Han Bi, Hai-Hong Jin, Jin Meng, Wei-Hong Zhao, Li Zhang, Ya-Fei Wang, Min Zheng, Xin Huang

Cell Rep Med 3(7) 100689

PMID35858589
PMCIDPMC9381412
DOI10.1016/j.xcrm.2022.100689
发表日期2022-07-20
摘要

摘要

This is a phase Ib study of anlotinib plus a programmed death-ligand 1 (PD-L1) inhibitor TQB2450 for platinum-resistant or -refractory ovarian cancer. Thirty-four patients are enrolled and receive treatment. The objective response rate (ORR) is 47.1%, and the disease control rate is 97.1%. The median duration of response (DOR) has not been reached, and 61.3% of patients have a DOR of at least 8 months. The median progression-free survival (PFS) is 7.8 months, and the median overall survival (OS) has not been reached. The PD-L1-positive group has an ORR of 25.0%, whereas the PD-L1-negative group has an ORR of 92.9%. Treatment-related grade 3 or 4 adverse events (AEs) occur in 70.6% of patients, with the most common being hypertension (29.4%) and palmar-plantar erythrodysesthesia syndrome (29.4%). Anlotinib plus TQB2450 show promising antitumor activity and manageable toxicities in patients with platinum-resistant or -refractory ovarian cancer. A phase 3 randomized controlled trial to further validate our findings is ongoing.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。